Clinical trials: Protein Digestion
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
- Trial name
- NCT04429542
- Testing
- BCA101, Pembrolizumab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 473 people
- Sponsor
- Bicara Therapeutics
Liver Cirrhosis, Kidney Failure, Acute
Intermittent ADVOS vs. Hemodialysis in Non-intensive Care Patients With Liver Dysfunction
In the planned randomized controlled prospective pilot study, we aim to evaluate ADVOS compared with conventional hemodialysis regarding the elimination of protein-bound toxins in patients with therapy-refractory hepatorenal…
- Conditions
- Liver Cirrhosis, Kidney Failure, Acute, Kidney Replacement, Multi Organ Failure
- Trial name
- ADVOMITTENT (NCT06129617)
- Testing
- Hemodialysis, ADVOS
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University Medical Center Mainz
Eosinophilic Esophagitis
Eosinophilic Oesophagitis Assessment With String Testing
Eosinophilic oesophagitis (EoE) is an inflammatory condition of the oesophagus (food pipe) that can lead to difficulty swallowing and to food to getting stuck and has become increasingly common over the past 40 years.
- Trial name
- EoEAST (NCT06159218)
- Testing
- CEST - coiled oesophageal string test
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Esophageal Cancer, Pancreas Cancer
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
The goal of this clinical trial is to investigate a new type of dendritic cell vaccine in patients with refractory or advanced solid tumors of the esophagus, liver, pancreas and ovaries.
- Conditions
- Esophageal Cancer, Pancreas Cancer, Ovarian Cancer, Liver Cancer
- Trial name
- IL15-TransDC (NCT05964361)
- Testing
- IL15-transpresenting WT1-targeted Dendritic Cell Vaccine
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Antwerp
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Inflammatory Bowel Diseases
The Role of Peripheral and Tissue Chitinase 3-like 1 Protein Levels as a Bio-marker in IBD
The digestive system may be involved in various pathologic conditions, with different inflammatory, metaplastic and neoplastic aspects.
- Trial name
- NCT03154905
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection
Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
Systemic treatment for advanced, non-resectable pancreatic cancer still having minimal impact on the survival of patients. Even with the application of more potent gemcitabine-based regimens, survival of more than 1 year is…
- Trial name
- NCT01198522
- Testing
- L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine
- Where
- 5 sites in Germany, Italy
- Volunteers
- 28 people
- Sponsor
- Philogen S.p.A.
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Colorectal Cancer, Resistance
Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)
Cancer-derived inflammation attenuates the efficacy of adjuvant chemotherapy (CT) in postoperative or metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer, Resistance, Bevacizimab, Inflamation
- Trial name
- NCT07241403
- Where
- China
- Volunteers
- 698 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Stomach Neoplasm, Lymph Node Metastasis
Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with 99mTc-3PRGD2 Probe.
Surgical lymph node dissection is the key to advanced gastric cancer. In recent years, after the overall implementation of standard D2 dissection, lymph node dissection for gastric cancer began to explore the direction of D1+…
- Conditions
- Stomach Neoplasm, Lymph Node Metastasis, RADIONUCLIDE IMAGING
- Trial name
- NCT06435741
- Testing
- 99mTc-3PRGD2 Spect-CT scan
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Type2 Diabetes, NAFLD
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
High-protein diets have been recently demonstrated to effectively reduce insulin resistance, derangements of the lipid profile and liver fat content in subjects with moderately and severely impaired glucose metabolism and…
- Trial name
- MOCA (NCT04564391)
- Testing
- protein supplement
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Cystic Fibrosis
Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients
YKL-40 is proposed as a biomarker of various inflammatory disease diabetes and lung disease including cystic fibrosis. In those cross-sectional studies, a unique value of YKL-40 is used to correlate with clinical, physiological…
- Trial name
- Kin_YKL_CF (NCT02305784)
- Where
- Canada
- Volunteers
- 188 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Advanced Solid Tumors, Hepatocellular Carcinoma
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC). Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B).
- Trial name
- NCT01668017
- Testing
- Pimasertib
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatitis B, Chronic
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.
- Trial name
- NCT03866187
- Testing
- ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation
- Where
- 43 sites in Belgium, France and 7 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Diarrhea-predominant Irritable Bowel Syndrome
Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D
To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction…
- Trial name
- NCT02163213
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Ischemia, Fatty Acid-Binding Proteins
Kidney and Intestinal Markers for Early Detection of Organ Injury After Endovascular Aortic Repair
This study aims to investigate the predictive value of novel biomarkers and contrast-enhanced ultrasonography for early detection of abdominal end-organ (kidney and intestinum) hypoperfusion and ischemia in patients undergoing…
- Conditions
- Ischemia, Fatty Acid-Binding Proteins, Mesenteric Vascular Disease, Acute Kidney Injury
- Trial name
- KISMED (NCT01915446)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Regensburg
Hepatitis B, Chronic
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
A multiple-center, open-label, Phase II clinical trial to evaluate the safety and the efficacy of HLX10 in chronic hepatitis B patients.
- Trial name
- NCT04133259
- Testing
- Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, Nucleoside/nucleotide analogues
- Where
- 3 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Henlix, Inc
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Inflammatory Bowel Diseases
Role of C-Reactive Protein /Albumin Ratio in Evaluation of Disease Activity in Patients With Inflammatory Bowel Disease
Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.
- Trial name
- NCT05738915
- Testing
- CRP/Albumin ratio in IBD
- Volunteers
- 100 people
- Sponsor
- Assiut University